NCT07022483 2026-02-04
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo
Phase 3 Recruiting
Daiichi Sankyo
Mabwell (Shanghai) Bioscience Co., Ltd.
GlaxoSmithKline
New Mexico Cancer Research Alliance
Cell Genesys
Cell Genesys